ESTRO 2025 - Abstract Book

S2143

Clinical - Urology

ESTRO 2025

Keywords: trimodality therapy, bladder cancer, immunotherapy

4572

Digital Poster Prostate cancer: Quality of life of patients after Image-guided radiation therapy (IGRT) with the new mono energetic accelerator Yosra Kochlef 1 , Amal Riahi 1 , Balkiss Ben Ali 1 , Amani Yousfi 1 , Hela Ayouni 2 , Ghaiet El Fida Noubbigh 3 , Lamia Zaabar 4 , Safia Yahiaoui 1 , Semia Zarraa 1 , Chiraz Nasr 1 1 Radiation oncology, Salah Azaiez Institute, Tunis, Tunisia. 2 Medical physics, Radiotherapy department, Salah Azaiez Institute, Higher Institute of Medical Technology of Tunis, Tunis, Tunisia. 3 Radiation oncology, Main Military Training Hospital of Tunis, Tunis, Tunisia. 4 Nuclear medicine department, Salah Azaiez Institute, Tunis, Tunisia Purpose/Objective: Prostate cancer is a common cancer whose symptoms are bothersome and impair the quality of life of patients. Image-guided radiation therapy (IGRT) is the reference technique in the treatment of prostate cancer, which has been widely used with linear accelerators that are constantly being developed. The fast-rotating coplanar kinetics with the new accelerator of the latest generation has been designed to improve the performance of radiation therapy accelerators, especially in terms of precision and protection of organs at risk. We started treating patients with the new accelerator in March 2024. The lack of data on the acute toxicity of the treatment with the new accelerator led us to conduct this study, the aim of which is to evaluate the quality of life of patients treated by the new single-energy machine in our establishment and to screen for the main acute toxicities related to it. Material/Methods: Our population consists of 21 patients aged between 57 and 75 years, followed for prostate cancer treated with hormone therapy and radiation therapy by the latest newly installed fast-rotating coplanar O-ring accelerator. The prescribed doses were between 12 Gy (patients undergoing treatment) and 76 Gy. We used the EORTC QLQ-PR25 questionnaire for the assessment of patients' quality of life during or after completion of radiotherapy. Results: Our population consisted of 21 patients with an average age of 66 years. All patients received hormone therapy and IGRT-type radiotherapy with the new accelerator. Urinary urgency was described in 18 patients before radiation therapy, 8 (38%) of whom had urinary incontinence, which significantly impaired their quality of life. After radiation therapy, urinary urgency persisted only for 8 of them (38%). Daily urination and nocturia decreased in 8 patients (38%) after radiotherapy, resulting in improved sleep quality. No patient reported the notion of worsening of urinary signs after radiotherapy. 3 patients (14%) reported the notion of acute diarrhea which resolved after radiotherapy. No cases of rectal bleeding have been reported after radiation therapy. Sexual disturbances were present in all patients before radiotherapy with no improvement afterwards. Only one patient (4.7%) reported the notion of worsening erectile dysfunction after radiotherapy. No deaths were recorded during radiotherapy. Conclusion: The new single-energy accelerator, designed to improve all aspects of the IGRT, appears to have acceptable radiation toxicities. Given the novelty of the start of treatment of our patients with this type of accelerator, additional follow-up is necessary to detect late toxicity and long-term tumor control.

Keywords: Prostate cancer, Quality of life , IGRT